Skip to main content
. 2016 Aug 18;3(2):257–270. doi: 10.1007/s40744-016-0041-3

Table 3.

Pain parameters 15 min after injection

Assessment, mean (SD) 40 mg/0.8 mL formulation 40 mg/0.4 mL formulation Within-patient differencea (95% CI) P valueb
Study 1 N = 62 N = 62
 Pain of injection 1.0 (1.52) 0.9 (1.66) –0.09 (–0.40 to 0.23) 0.581
 Present pain intensity 0.3 (0.54) 0.2 (0.48) –0.05 (–0.22 to 0.13) 0.584
 MPQ-SF pain experience
  Sensory dimension score 0.8 (1.83) 0.6 (2.14) –0.13 (–0.73 to 0.48) 0.671
  Affective dimension score 0.1 (0.65) 0.1 (0.58) –0.03 (–0.24 to 0.17) 0.754
  Total score 0.9 (2.32) 0.7 (2.64) –0.16 (–0.93 to 0.61) 0.678
Study 2 N = 60 N = 60
 Pain of injection 1.0 (1.61) 0.4 (1.08) –0.62 (–1.08 to –0.17) 0.008
 Present pain intensity 0.7 (0.86) 0.2 (0.53) –0.42 (–0.62 to –0.22) <0.001
 MPQ-SF pain experience
  Sensory dimension score 1.5 (2.84) 0.4 (0.92) –1.17 (–1.81 to –0.52) <0.001
  Affective dimension score 0.1 (0.25) 0.1 (0.36) 0 (–0.09 to 0.10) 0.963
  Total score 1.6 (2.88) 0.5 (1.03) –1.17 (–1.81 to –0.52) <0.001

ANOVA analysis of variance, CI confidence interval, MPQ-SF short-form McGill Pain Questionnaire, SD standard deviation

aWithin-patient difference for 40 mg/0.4 mL adalimumab–40 mg/0.8 mL adalimumab from the crossover ANOVA model with period, sequence, and treatment as fixed effects, and subject as a random effect

bFor differences between treatment groups from ANOVA with period, sequence, and treatment as fixed effects, and subject as a random effect